We want to make it easy for our patients to manage and navigate the financial toxicity they encounter from their cancer care, noted Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health and the Allina Health Cancer Institute.
We want to make it easy for our patients to manage and navigate the financial toxicity they encounter from their cancer care, and for that we provide foundation and copay assistance, as well as look at optimizing insurance coverage, noted Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health and the Allina Health Cancer Institute.
Transcript
Can you discuss some initiatives Allina Health has to address financial toxicity in oncology?
I’m passionate about addressing the financial toxicity of cancer care. I can't control the cost of drugs and oftentimes, too, just the cost of health care, even though that is an impediment, too, of addressing the total cost of care. But what I'm proud to roll out is a robust and comprehensive patient financial navigation program. It's not only maximizing, for our patients, the use of outside foundation and copay assistance, but it's also looking at insurance optimization and other aspects to decrease the financial toxicity. We know from our internal studies, too, that our patients’ anxiety is higher around the financial aspects than it is even over the diagnosis itself.
So my goal is at all of our sites, both virtually and in person, to elevate through our software to make it easy to manage and navigate all the foundations to address the financial toxicity, which is also a population health initiative, too.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Health Equity & Access Weekly Roundup: April 14, 2025
April 14th 2025From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Health Equity & Access Weekly Roundup: April 14, 2025
April 14th 2025From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
2 Commerce Drive
Cranbury, NJ 08512